Man settles action against HSE over wife's death at Cork hospital for €90,000
A man who sued over the sudden and unexpected death of his wife at Mallow General Hospital five years ago has settled a High Court action for €90,000.
Katherine Heneghan (71), a mother of five and grandmother to 13, died as a result of a blood clot on September 10th, 2020.
Advertisement
The family's counsel, Dr John O'Mahony SC with Doireann O'Mahony BL, told the High Court there was a 'bed issue' at Cork University Hospital and Mrs Heneghan had been admitted to the Mallow hospital.
Dr O'Mahony said it was their case that at Mallow General Hospital the pensioner was allegedly not tested properly and not screened appropriately in relation to blood clots and if she had been given blood thinners she may have survived.
Dr O'Mahony said it was a very sad death and Mrs Heneghan was a 'dearly loved wife, mother and grandmother.'
The settlement against the HSE is without an admission of liability.
Advertisement
At the time of her death Mrs Henegan and her husband Philip had been married for 55 years.
In the proceedings it was claimed that when Mr Heneghan arrived at Mallow General Hospital on September 10th, he was given the news of his wife's death in a hospital lift by a nurse and he nearly passed out with shock.
Philip Heneghan (83), of Mallow, Co Cork, sued the HSE over his wife's death.
Mrs Heneghan, who had been complaining of shortness of breath and had a swelling on her leg, was seen at Mallow General Hospital and kept in overnight on September 9th, 2020.
Advertisement
It was claimed there was no assessment of Mrs Heneghan in relation to the probability of a blood clot by the admitting medical team at the hospital.
It was also alleged that if there had been such an assessment it would have become apparent there was a moderate to high risk of the pensioner developing a blood clot.
Mrs Heneghan would have survived if the medical team had considered pulmonary embolism as a possible diagnosis, it was claimed.
It was also claimed that a breathless patient presenting to a hospital emergency department needs to have a blood clot considered as part of the differential diagnosis, and there was allegedly no documentation that this was considered a possibility in Mrs Heneghan's case.
Advertisement
Ireland
Limerick feud escalates: House demolished after bo...
Read More
It was further claimed that there was a failure to deliver a reasonable and safe standard of care and a failure to assess for the possibility of a blood clot, and Mrs Heneghan had allegedly been deprived of the chance of survival.
It was contended that the news of his wife's sudden death had been delivered unprofessionally, causing Mr Henegan profound shock and distress.
All of the claims were denied.
Noting the settlement, Mr Justice Paul Coffey conveyed his deepest sympathy to Mr Heneghan and the wider family.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
17 hours ago
- BBC News
US demand for weight loss drugs drives Irish exports
A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the United States, the central bank in Dublin has said. The main reason for the big rise in Irish exports was businesses getting goods into the US before President Donald Trump's tariffs took effect in April. March was a record month for Irish exports to the US with sales worth $25bn (£18.7bn), 400% higher than the same period in 2024. The Central Bank of Ireland said this surge was "concentrated in a single product category: ingredients used in weight loss and diabetes medicines". It added that when the tariff effect was stripped out there was "some evidence of strong momentum in underlying goods exports related to weight loss products, ingredients for which are manufactured in Ireland". "The pharmaceutical sector in Ireland appears well placed to take advantage of rapidly rising global demand for these products." Weight loss drugs manufactured in Ireland The US firm Eli Lilly makes the active pharmaceutical ingredients for its Zepbound and Mounjaro weight loss treatments near Kinsale in County Cork. Earlier this decade it invested $800m (£597m) in the Cork facility to help meet anticipated demand for the drug. Eli Lilly said in the first quarter of 2025 its sales of the drugs were worth just over $6bn (£4.5bn) compared to $2.3bn (£1.7bn) in the same period in 2024. Zepbound and Mounjaro are among a class of drugs which work as an appetite suppressant by mimicking a hormone called glucagon-like peptide-1 (GLP-1). This is an intestinal hormone which is released after eating, and typically makes people feel fuller. Most of the US's major pharmaceutical companies have manufacturing operations in Ireland, partially for tax reasons. That has made the US Ireland's biggest export market with pharmaceuticals the most important sector. Trump has not yet imposed tariffs on pharmaceuticals but is threatening to do so on national security grounds. Until that happens the majority of Irish goods exported to the US do not face tariffs.
BreakingNews.ie
19 hours ago
- BreakingNews.ie
Galway hospital apologises for misdiagnosis of girl's appendicitis as she settles for €64,000
A hospital has apologised to a young girl whose appendicitis was allegedly misdiagnosed and her appendix later ruptured. A letter of apology from University Hospital Galway was read in the High Court as Ariana Mocanu settled a legal action against the HSE for €64,000. Advertisement Her counsel, Jeremy Maher SC, instructed by PBN Litigation, told the court that the girl, who was 7 years old at the time, had at the hospital been incorrectly diagnosed with a urinary tract infection and discharged home after midnight with antibiotics. Nine hours later, Mr Maher said she was brought back to the hospital, but her acute appendicitis had progressed to a perforated appendix and peritonitis, and she required urgent surgery. Mr Maher said the girl's father had on several occasions raised the possibility of appendicitis with the hospital treating medic, but was told it was a urinary tract infection. Mr Justice Paul Coffey was told that liability and causation remained at issue in the case. Advertisement In the letter which was read to the court, University Hospital Galway said Ariana had been assessed by an emergency medicine doctor who formed the opinion based on her presenting complaints that the diagnosis was more likely to be a urinary tract infection rather than appendicitis. 'On this occasion, the diagnosis turned out to be incorrect. The hospital apologises for this initial misdiagnosis,' the letter from the hospital manager, Chris Kane, said. It added: 'We regret what Ariana and her family went through and we wish Ariana and her family the very best.' Mr Maher told the court experts on their side would say there was never a case where she should have been sent home. Advertisement He said the HSE contended surgery would not have been possible before morning at the hospital in any event, which Counsel said he found to be bizarre. Ariana had to have open surgery the next day and counsel said she had shown incredible courage. Outside court, the girl's parents, Diana and Petru Mocanu through solicitor Piarais Neary, said they had brought the case for Ariana and to highlight to other parents the risk of appendicitis and to know the signs and when to seek urgent medical treatment. They said they welcomed the apology after three years. Advertisement Ariana Mocanu, of Gorey, Co Wexford, had through her father, Petru Mocanu, sued the HSE. The little girl had been brought to University Hospital Galway accident and emergency department on July 23rd, 2022, complaining of acute central abdominal pain, nausea and vomiting. In the proceedings, it was claimed there was a failure to take any or any reasonable care for the safety of the little girl and a failure to exercise an appropriate level of care, skill, competence and diligence in or about the diagnosis, assessment, management and treatment of the child when she presented at the hospital emergency department on July 23rd, 2022. The little girl, it was contended, had been subjected to a substandard level of care when she presented at the hospital A&E, and there had been a wrong diagnosis of urinary tract infection. The little girl, it was claimed, had been discharged with a wrong diagnosis and instead she should have been admitted to the hospital. All of the claims were denied. Approving the settlement, Mr Justice Paul Coffey said he was satisfied it was fair and reasonable.
The Independent
21 hours ago
- The Independent
New schemes to ease flow of veterinary medicines into Northern Ireland
The Government has announced two schemes designed to ease the flow of veterinary medicines from Great Britain into Northern Ireland when a post-Brexit grace period expires at the end of the year. EU rules on the medicines will apply in Northern Ireland from January 1, which will place restrictions on the supply of products from the rest of the UK, with GB suppliers needing to make adaptations to continue to sell into the region. The changes have raised concerns among the veterinary profession that some critical products that vets traditionally source from across the Irish Sea will no longer be available. Government officials have undertaken 18 months of extensive research with the pharmaceutical industry to identify issues, and determined that the problem will not be as significant as some initial predictions, with only a small number of critical medicines – where no alternative is available – being discontinued in Northern Ireland. The Government is introducing two schemes to ensure vets can continue to access these medicines from GB once the grace period ends. The details were outlined in a policy paper published by Northern Ireland Secretary Hilary Benn on Thursday. The Veterinary Medicines Internal Market Scheme pledges to streamline the process of securing the restricted medicines from GB. While vets will be asked to consider if a similar product is available in the EU, they will be able to proceed with purchasing it from GB if they determine the cost or time taken to import it from Europe would be prohibitive. Vets will also be able to pre-emptively secure the medicines so they have stock at hand when required. The requirement for a special import certificate to move the medicines from GB to NI will also be removed. The second initiative, the Veterinary Medicines Health Situation Scheme, is being set up to monitor the industry to identify potential discontinuation issues as they emerge and ensure a supply of alternative medicines are made available. While the schemes have not been designed in conjunction with the EU, the Government insists the initiatives will be in full compliance with EU law. Mr Benn outlined the plans in a written ministerial statement. He said ensuring the supply of veterinary medicines to Northern Ireland was of 'critical importance'. 'To that end we have seen significant progress as large sections of the pharmaceutical industry have taken and are taking the steps needed to continue to supply veterinary medicines to Northern Ireland,' he said. 'This means that in the vast majority of cases, vets, farmers and pet owners will continue to have access to the medicines they need. But I recognise that even a small disruption could cause real difficulties, and that there are understandable concerns in those limited areas where supply may be disrupted and there are no alternative products authorised or available in Northern Ireland. 'Therefore, the Government is taking further measures to ensure access to veterinary medicines in such cases, as set out in the paper.' Mr Benn added: 'The combination of progress to date on the adaptation by industry and the measures set out in the paper means that the Government is confident that Northern Ireland will continue to enjoy access to the veterinary medicines necessary to protect the health and welfare of animals, and the livelihoods of farmers and veterinary surgeons. 'Further guidance will be issued in due course and we will continue to monitor emerging risks to animal health and veterinary medicine availability. Intensive engagement will continue through 2025 and beyond to address any gaps. 'Where they have yet to do so, we are encouraging the pharmaceutical industry to make any necessary changes as soon as possible.'
